NEW YORK, Sept 27 (Reuters) - U.S. drugmaker Abbott Laboratories is expected to buy Solvay SA's pharmaceuticals unit for 4.5 billion euros ($6.6 billion), with an announcement planned in the next 24 hours, a source familiar with the situation said on Sunday.
The all-cash deal between the companies, which co-market the blockbuster drug Tricor for controlling blood fats called triglycerides, would give Abbott a number of new medicines in late-stages of
freshwater pearl beads testing and an entrance into the fast-growing business of vaccines.
Article Controls
'Abbott has no vaccines and this is a growing global market, so this is definitely an element that is attracting Abbott,' the
freshwater loose pearl source said, noting that Solvay's relatively small vaccines business is focused on influenza.
The deal would also broaden Abbott's current presence in emerging markets, a mushrooming focus for healthcare companies that can no longer count on sizzling revenue growth from the mature U.S. market.
The copying, republication or redistribution of
pearl bracelet Reuters News Content, including by framing or similar means, is expressly prohibited without the prior written consent of Thomson Reuters.
Neither the Subscriber nor
cultured freshwater pearlThomson Reuters warrants the completeness or accuracy of the Service or the suitability of the Service as a trading aid and neither accepts any liability for losses howsoever incurred. The content on this site, including news, quotes, data and other information, is provided by Thomson Reuters and its third party content providers for your personal information only, and neither Thomson Reuters nor its third party content providers shall be liable for any errors, inaccuracies or delays in content, or for
white pearl any actions taken in reliance thereon.
Posted at 01:02 am by wholesale114
Permalink